Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
about
Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Cost-effectiveness analysis of ...... with the new 2-dose schedule.
@ast
Cost-effectiveness analysis of ...... with the new 2-dose schedule.
@en
type
label
Cost-effectiveness analysis of ...... with the new 2-dose schedule.
@ast
Cost-effectiveness analysis of ...... with the new 2-dose schedule.
@en
prefLabel
Cost-effectiveness analysis of ...... with the new 2-dose schedule.
@ast
Cost-effectiveness analysis of ...... with the new 2-dose schedule.
@en
P2093
P2860
P1476
Cost-effectiveness analysis of ...... with the new 2-dose schedule.
@en
P2093
Benjamin Cuenca
Carrie Purugganan
Georges Van Kriekinge
I-Heng Lee
Ma Socorro Bernardino
Maria Julieta Germar
Y-Chen Chen
P2860
P304
P356
10.1080/21645515.2016.1269991
P577
2017-01-11T00:00:00Z